A Comparative Efficacy of Atezolizumab plus Bevacizumab Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Review

Kristin Talia Marbun, Juandy Jo

Abstract


Hepatocellular carcinoma (HCC) ranks sixth as the most common cancer and fourth as the most common cause of cancer-related death globally. The standard treatment for advanced HCC is by prescribing sorafenib, a tyrosine kinase inhibitor. Despite its moderate efficacy and concerning side effects, there is no better alternative to sorafenib to treat HCC. However, a new combination of atezolizumab (an inhibitor of PD-L1) and bevacizumab (an inhibitor of vascular endothelial growth factor), has shown a potential to surpass the efficacy of sorafenib. This review was written to provide an insight into pharmacodynamics of sorafenib and atezolizumab plus bevacizumab, effectiveness of sorafenib and the one of atezolizumab plus bevacizumab, utilization of atezolizumab plus bevacizumab in the clinical practice, as well as to argue that this combination can replace sorafenib as the standard palliative treatment for HCC.


Keywords


Hepatocellular carcinoma; Sorafenib; Atezolizumab; Bevacizumab



DOI: http://dx.doi.org/10.19166/med.v10i2.7023

Full Text:

PDF

References


1. El-Serag H, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?. Hepatology. 2014;60(5):1767-1775. https://doi.org/10.1002/hep.27222

2. Ziogas I, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology. 2017;8(3):203. https://doi.org/10.5306%2Fwjco.v8.i3.203

3. Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine. 2020;382(20):1894-1905. https://doi.org/10.1056/nejmoa1915745

4. National Cancer Institute. Milestones in Cancer Research and Discovery [Internet]. National Cancer Institute. 2020 [cited 10 April 2022]. Available from: https://www.cancer.gov/research/progress/250-years-milestones

5. Dimri M, Satyanarayana A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers. 2020;12(2):491. https://doi.org/10.3390/cancers12020491

6. Bao M, Wong C. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7):1715. https://doi.org/10.3390%2Fcells10071715

7. Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomarkers in Cancer. 2016;8s1:BIC.S34413. https://doi.org/10.4137%2FBIC.S34413

8. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Research. 2020;30(8):660-669. https://doi.org/10.1038/s41422-020-0343-4

9. Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in Immunology. 2020;11. https://doi.org/10.3389%2Ffimmu.2020.01956

10. Wang T, Zhang K. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Frontiers in Oncology. 2020;10. https://doi.org/10.3389%2Ffonc.2020.01316

11. Tsoris A, Marlar C. Use Of The Child Pugh Score In Liver Disease [Internet]. Ncbi.nlm.nih.gov. 2022 [cited 11 April 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542308/

12. Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T et al. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer. 2020;9(6):734- 743. https://doi.org/10.1159/000508971

13. Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C et al. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers. 2022;14(7):1722. https://doi.org/10.3390/cancers14071722

14. Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen D, Koorey D et al. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World Journal of Gastroenterology. 2017;23(15):2763. https://doi.org/10.3748%2Fwjg.v23.i15.2763

15. Noda Y, Kawaguchi T, Kuromatsu R, Komukai S, Nakano M, Niizeki T et al. Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis. Oncology Letters. 2019;. 18(1):227-236. https://doi.org/10.3892/ol.2019.10285

16. Gong L, Giacomini M, Giacomini C, Maitland M, Altman R, Klein T. PharmGKB summary. Pharmacogenetics and Genomics. 2017;27(6):240-246. https://doi.org/10.1097%2FFPC.0000000000000279

17. Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduction and Targeted Therapy. 2020;5(1):1-15. https://doi.org/10.1038/s41392-020-0187-x

18. Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatology Research. 2012;43(2):147-154. https://doi.org/10.1111%2Fj.1872-034X.2012.01113.x

19. Molina-Ruiz F, Gonzalez R, Rodriguez-Hernandez M, Navarro-Villaran E, Padillo F, Muntané J. Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress. Critical ReviewsTM in Oncogenesis. 2016;21(5-6):413-432. https://doi.org/10.1615/critrevoncog.2017021302

20. Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncology. 2021;17(17):2243-2256. https://doi.org/10.2217/fon-2020-1290

21. Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M et al. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 2021;13(11):2786. https://doi.org/10.3390/cancers13112786

22. Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y et al. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatology Research. 2021;51(9):979-989. https://doi.org/10.1111/hepr.13693

23. Hato T, Zhu A, Duda D. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016;8(3):299-313. https://doi.org/10.2217/imt.15.126

24. Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine. 2020;9(3):675. https://doi.org/10.3390/jcm9030675

25. Lee W, Yang H, Chon H, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental & Molecular Medicine. 2020;52(9):1475-1485. https://doi.org/10.1038/s12276-020-00500-y

26. Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Reviews Clinical Oncology. 2018;15(5):325-340. https://doi.org/10.1038/nrclinonc.2018.29

27. Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2021;39(3_suppl):267-267. http://dx.doi.org/10.1200/JCO.2021.39.3_suppl.267

28. Food & Drug Administration. FDA approves atezolizumab plus bevacizumab for unresectable hepatocell. U.S. Food and Drug Administration. 2022. Browsed: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma


Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Kristin Talia Marbun, Juandy Jo

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

 

Creative Commons License

MEDICINUS is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Copyright © Fakultas Kedokteran | Universitas Pelita Harapan | Lippo Karawaci, Tangerang, Indonesia, 15811 . All rights reserved. p-ISSN 1978-3094 | e-ISSN 2622-6995